Breaking News

Recipharm, PledPharma in Supply Pact

February 13, 2013

Manufactures material for Phase II PLIANT trial

Recipharm will supply clinical trial materials to PledPharma for its Phase IIb trial with PledOx, PLIANT, following the FDA’s IND approval. The material for PLIANT has been manufactured by Recipharm Pharmaceutical Development.
 
Recipharm Pharamaceutical Development’s general manager, Maria Lundberg, said, “We are delighted to contribute to the development of a new product that may reduce serious side-effects of the chemotherapy in patients treated for advanced colorectal cancer. Furthermore, manufacturing material for an FDA-approved clinical study reflects the highest standards of service quality and capabilities that Recipharm provides to its customers, meeting the expectations and demands of today’s competitive market place.”
 
Jacques Näsström, chief executive officer of PledPharma, said, "We are very pleased with the positive assessment by the FDA. Since the U.S. is perhaps the single most important market, it is particularly encouraging that we received approval for our study there.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016